MARKET

CLLS

CLLS

Cellectis
NASDAQ

Real-time Quotes | Nasdaq Last Sale

16.30
+0.77
+4.96%
Closed 17:14 05/07 EDT
OPEN
16.08
PREV CLOSE
15.53
HIGH
17.05
LOW
15.81
VOLUME
248.00K
TURNOVER
--
52 WEEK HIGH
34.71
52 WEEK LOW
13.17
MARKET CAP
697.32M
P/E (TTM)
-8.5501
1D
5D
1M
3M
1Y
5Y
William Blair Thinks Cellectis SA’s Stock is Going to Recover
SmarterAnalyst · 3d ago
BRIEF-Cellectis SA Says Qtrly Loss Per Share $0.28
reuters.com · 3d ago
Cellectis Q1 EPS $(0.26) Down From $0.57 YoY, Sales $27.97M Down From $51.91M YoY
Cellectis (NASDAQ:CLLS) reported quarterly losses of $(0.26) per share. This is a 145.61 percent decrease over earnings of $0.57 per share from the same period last year. The company reported $27.97 million in sales
Benzinga · 3d ago
BRIEF-Cellectis Posts Quarterly EPS Of $0.47
reuters.com · 3d ago
Cellectis EPS beats by $0.52, beats on revenue
Cellectis (CLLS): Q1 Non-GAAP EPS of -$0.26 beats by $0.52; GAAP EPS of -$0.28 beats by $0.73.Revenue of $27.97M (-46.1% Y/Y) beats by $19.88M.Press Release
Seekingalpha · 3d ago
Cellectis Provides Business Update and Reports Financial Results for First Quarter 2021
-- Enrollment ongoing in three Cellectis-sponsored Phase 1 dose-escalation clinical studies BALLI-01 in r/r B-ALL patients, AMELI-01 in r/r AML patients and MELANI-01 in r/r MM patients in 15 US clinical centers
GlobeNewswire · 3d ago
Cellectis SA (CLLS) Receives a Buy from Robert W. Baird
SmarterAnalyst · 04/29 08:51
William Blair Sticks to Their Buy Rating for Cellectis SA (CLLS)
In a report released today, Raju Prasad from William Blair maintained a Buy rating on Cellectis SA (CLLS). The company's shares closed last Wednesday at
SmarterAnalyst · 04/28 16:32
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CLLS. Analyze the recent business situations of Cellectis through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 11 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CLLS stock price target is 34.89 with a high estimate of 50.00 and a low estimate of 11.00.
EPS
Institutional Holdings
Institutions: 133
Institutional Holdings: 17.70M
% Owned: 41.36%
Shares Outstanding: 42.78M
TypeInstitutionsShares
Increased
23
3.54M
New
30
453.17K
Decreased
24
941.76K
Sold Out
13
961.66K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.53%
Pharmaceuticals & Medical Research
+1.04%
Key Executives
Non-Executive Chairman
Jean-Pierre Garnier
Chief Executive Officer/Co-Founder/Executive Board/Director
Andre Choulika
Co-Founder/Executive Vice President/Executive Board/Director
David Sourdive
Executive Vice President/Executive Board
Bill Montelth
Chief Financial Officer/Executive Board
Eric Dutang
Chief Human Resource Officer/Executive Vice President/Executive Board
Kyung Nam-Wortman
Executive Vice President/Executive Board
Jon Voss
Senior Vice President/Executive Board
Leopold Bertea
Vice President
Francisco Esteva
Senior Vice President/Executive Board
Steven Doares
Senior Vice President
Steve Doares
Senior Vice President
Mark Frattini
Chief Scientific Officer/Executive Board
Philippe Duchateau
Chief Compliance Officer/Executive Board
Stephan Reynier
General Counsel/Executive Board
Marie-Bleuenn Terrier
Executive Board
Carrie Brownstein
Executive Board
Arthur Stril
Non-Executive Independent Director
Laurent Arthaud
Non-Executive Independent Director
Pierre Bastid
Non-Executive Independent Director
Rainer Boehm
Non-Executive Independent Director
Alain Godard
Non-Executive Independent Director
Herve Hoppenot
Non-Executive Independent Director
Annick Schwebig
No Data
  • All
  • Financials
  • Insiders
More
About CLLS
Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development, and commercialization of rational genome engineering technologies. The Company develops immunotherapies that aim to force the immune system to target and eradicate cancer cells. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement. Cellectis SA markets its technologies mainly for use in the research field, in pharmaceutical drug discovery programs, in the agronomics, bioproduction, and biotherapeutics fields. Cellectis SA operates several subsidiaries. The Company operates in France and the United States, among others.

Webull offers kinds of Cellectis SA (ADR) stock information, including NASDAQ:CLLS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CLLS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CLLS stock methods without spending real money on the virtual paper trading platform.